Proactive Investors - Run By Investors For Investors

Verona Pharma starts Asthma drug trial

Verona Pharma starts Asthma drug trial

Verona Pharma (LON:VRP) has begun a new clinical trial to evaluate higher dosing of its key asthma drug, RPL554.

The trial will help Verona set the dosage for a subsequent trial, which will test the drug's effectiveness over a period of days. 

The second trial will also assess the anti-inflammatory effect of the drug.

"We are delighted that this trial to further clarify the therapeutic usefulness of RPL554 is underway,” chief executive Professor Michael Walker said.

“We believe that, combined with the second trial, we will demonstrate the safety of RPL554 at higher doses as well as its significant potential as a bronchodilator and anti-inflammatory drug,

“The trials are expected to add value and satisfy questions raised by potential development partners in the company's licensing discussions which are ongoing."

The first patient in the trial has now been treated at the Centre for Human Drug Research (CHDR) in Leiden, The Netherlands.

The asthma drug is designed to inhibit two enzymes that are known to effect the development and progression of inflammatory respiratory diseases.

Verona highlighted that a previous Phase I/IIa trial demonstrated safety and effective bronchodilation, using lower doses.

 

View full VRP profile View Profile

Verona Pharma Timeline

Article
June 20 2016
Newswire
November 26 2010

Related Articles

rasuvo
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
woman's face
Tue
Here we take a closer look at SkinBioTherapeutics, the life sciences group that is using bacteria to improve people’s skin
antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use